Verastem Inc (NASDAQ:VSTM)

7.66
Delayed Data
As of Jun 22
 0.00 / 0.00%
Today’s Change
2.05
Today|||52-Week Range
9.07
+149.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$291.6M

Company Description

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.

Contact Information

Verastem, Inc.
117 Kendrick Street
Needham Massachusetts 02494
P:(781) 292-4200
Investor Relations:
(781) 292-4214

Employees

Shareholders

Individual stakeholders18.39%
Other institutional15.41%
Mutual fund holders10.99%

Top Executives

Robert M. ForresterPresident, Chief Executive Officer & Director
Dan PatersonChief Operating, Financial & Accounting Officer
Jonathan PachterChief Scientific Officer
Diep LeChief Medical Officer
Joseph M. LobackiChief Commercial Officer & Executive VP